Cidara Therapeutics Inc

NASDAQ:CDTXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company’s primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples’ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.

Contact Information

Headquarters

6310 Nancy Ridge Dr Ste 101SAN DIEGO, CA, United States 92121-3209

Phone

858-752-6170

Fax

302-655-5049

Executives

Independent Chairman of the Board

Daniel Burgess

President, Chief Executive Officer, Chief Financial Officer, Director

Jeffrey Stein

Chief Financial Officer, Chief Business Officer

Preetam Shah

Chief Operating Officer, Company Secretary

Shane Ward

Chief Scientific Officer

Leslie Tari